After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

NeuroVision, which is working toward regulatory approval for its early Alzheimer’s detection technology, has acquired fellow diagnostics maker Durin Life Sciences for an undisclosed price. With the ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments (eCOA) ...

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

Aptose Biosciences has scrapped a deal for a blood cancer drug candidate as part of its pending takeover by Hanmi ...

Global contract research organization Icon has announced the opening of a new research facility in San Antonio, Texas, along ...